Fineline Cube

Follow:
14398 Articles
GenEditBio's GEB-101 Wins FDA IND Approval as World's First Corneal Gene Therapy
CompanyDrug

GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy

Merck's Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension
CompanyDrug

Merck’s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion
CompanyDeals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion
CompanyDeals

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
CompanyDrug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
CompanyDeals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio
CompanyDrug

Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio

NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support
Policy / Regulatory

NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy
CompanyDrug

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy

China State Council Approves Revised Drug Administration Regulations, Accelerating Innovation Review
Policy / Regulatory

China State Council Approves Revised Drug Administration Regulations, Accelerating Innovation Review

Aosaikang Licenses Adlai Nortye's Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
CompanyDeals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
CompanyDrug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review